Role of immunotherapy in localized muscle invasive urothelial cancer

by Jasmeet Kaur, Woonyoung Choi, Daniel M. Geynisman, Elizabeth R. Plimack, Pooja Ghatalia
Published 2021-09-01

Muscle-invasive urothelial bladder cancer: an update on systemic therapy

by Hayley Knollman, J. Luke Godwin, Rishi Jain, Yu-Ning Wong, Elizabeth R. Plimack, Daniel M. Geynisman
Published 2015-12-01

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

by Gary D Steinberg, Neal Shore, Petros Grivas, Matthew D Galsky, Elizabeth R Plimack, Shilpa Gupta, Arjun V Balar, Peter C Black, Matthew T Campbell, Gail S Dykstra, Christoper J Hoimes, Lidia P Lopez, Joshua J Meeks, Jonathan E Rosenberg, Ashish M Kamat
Published 2021-07-01

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

by Michael Hurwitz, Mark Stein, Jeffrey Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Meredith M Regan, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Paul J Catalano
Published 2024-04-01

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

by Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers
Published 2018-10-01

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

by Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, Lionel D. Lewis, Todd M. Bauer, David F. McDermott, Michael Carducci, Christian Kollmannsberger, Brian I. Rini, Daniel Y. C. Heng, Jennifer Knox, Martin H. Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J. Hammers
Published 2019-03-01

Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer

by Jeffrey S. Damrauer, Wolfgang Beckabir, Jeff Klomp, Mi Zhou, Elizabeth R. Plimack, Matthew D. Galsky, Petros Grivas, Noah M. Hahn, Peter H. O’Donnell, Gopa Iyer, David I. Quinn, Benjamin G. Vincent, Diane Zipursky Quale, Sara E. Wobker, Katherine A. Hoadley, William Y. Kim, Matthew I. Milowsky
Published 2022-11-01

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

by Howard Gurney, Thomas Powles, Laurence Albiges, Camillo Porta, Toni K Choueiri, Marc-Oliver Grimm, Elizabeth R Plimack, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Philippe Barthélémy, Christian K Kollmannsberger, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir, Mauricio Burotto, Daniel Castellano
Published 2020-12-01

A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors

by Matthew Zibelman, Alexander W. MacFarlane, Kimberly Costello, Thomas McGowan, John O’Neill, Rutika Kokate, Hossein Borghaei, Crystal S. Denlinger, Efrat Dotan, Daniel M. Geynisman, Angela Jain, Lainie Martin, Elias Obeid, Karthik Devarajan, Karen Ruth, R. Katherine Alpaugh, Essel Al-Saleem Dulaimi, Edna Cukierman, Margret Einarson, Kerry S. Campbell, Elizabeth R. Plimack
Published 2023-07-01

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database

by Gabriella Del Bene, Fabio Calabrò, Diana Giannarelli, Elizabeth R. Plimack, Lauren C. Harshman, Evan Y. Yu, Simon J. Crabb, Sumanta Kumar Pal, Ajjai S. Alva, Thomas Powles, Ugo De Giorgi, Neeraj Agarwal, Aristotelis Bamias, Sylvain Ladoire, Andrea Necchi, Ulka N. Vaishampayan, Günter Niegisch, Joaquim Bellmunt, Jack Baniel, Matthew D. Galsky, Cora N. Sternberg
Published 2018-11-01

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

by Alessia Cimadamore, Michael Hurwitz, Mark Stein, Sabina Signoretti, Jeffrey A Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Thomas Denize, Catherine J Wu, David Braun, Paul J Catalano
Published 2023-03-01

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer

by David Liu, Philip Abbosh, Daniel Keliher, Brendan Reardon, Diana Miao, Kent Mouw, Amaro Weiner-Taylor, Stephanie Wankowicz, Garam Han, Min Yuen Teo, Catharine Cipolla, Jaegil Kim, Gopa Iyer, Hikmat Al-Ahmadie, Essel Dulaimi, David Y. T. Chen, R. Katherine Alpaugh, Jean Hoffman-Censits, Levi A. Garraway, Gad Getz, Scott L. Carter, Joaquim Bellmunt, Elizabeth R. Plimack, Jonathan E. Rosenberg, Eliezer M. Van Allen
Published 2017-12-01

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a random...

by Howard Gurney, Thomas Powles, Asim Amin, Bohuslav Melichar, Camillo Porta, David F McDermott, Toni K Choueiri, Marc-Oliver Grimm, Bernard Escudier, Elizabeth R Plimack, Brian I Rini, Hans J Hammers, Saby George, Robert J Motzer, Alain Ravaud, Osvaldo Arén Frontera, Frede Donskov, Philippe Barthélémy, Victoria Neiman, Pamela Salman, Christian K Kollmannsberger, Scott S Tykodi, Raya Leibowitz-Amit, Poul F Geertsen, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir
Published 2020-07-01